Evicenter
MarkdownMedical informationP&T meetings
Psilocybin (COMP360)

Treatment-resistant depression

Manufacturer
COMPASS Pathways
Last updated
261 sources

Economic information and modeling report

Modeling overview

15 evidence topics · 15 sources

Summary

No source in this report presents a cost-effectiveness or budget impact model of COMP360 itself, and none quotes a price for it. ICER is assessing synthetic psilocybin against esketamine or intravenous ketamine and repetitive transcranial magnetic stimulation, with a model analysis plan due January 22, 2027, a five-year health care system cost-effectiveness model, and a separate five-year budget impact analysis; its final evidence report is scheduled for 06/21/2027. Published analyses of psilocybin therapy report $117,517 per QALY gained over 12 months from a limited healthcare perspective, cost savings of approximately $7000 per patient compared with standard of care, and cost-effectiveness when the cost of therapist support was reduced by 50% and the psilocybin price to £400 to £800 per person. For the comparator, ICER's 2019 report estimated approximately $198,000 per QALY gained for esketamine. The company plans drug reimbursement through the pharmacy benefit and monitoring through CPT Category III codes, and presented health economics posters on real-world costs across TRD health states at Psych Congress 2026. A payer panel noted that the effect of psilocybin on later treatment needs leaves “an uncertain impact to the total cost of care.”